ABSTRACT
Background: The most common cranial mediastinal masses affecting dogs and cats include lymphoma and thymic epithelial tumors. In this report, a cat with a cranial mediastinal mass was diagnosed with a thymic carcinoma subtype squamous cell carcinoma, which has rarely been reported in cats. Management of this subtype with a combination of surgery and chemotherapy has so far not been reported. This case report describes the treatment with surgical management followed by intracavitary carboplatin. Case Description: A 12-year-old male neutered domestic short hair cat was referred for lethargy, hyporexia, and weight loss, and was diagnosed with a cranial mediastinal mass radiographically. Initial cytology through fine needle aspirates was suggestive of carcinoma. Computed tomography was performed which did not show evidence of other primary tumor sources or metastases, and hence surgical resection was recommended. Intraoperative findings revealed local invasion of the surrounding tissues, including major vasculature and nerves, although histopathological assessment showed no local lymph node involvement. Intracavitary carboplatin chemotherapy was administered 2 weeks postsurgery. The patient was humanely euthanized 4 weeks postsurgery due to evidence of local recurrence causing significant respiratory compromise. Conclusion: A combination of surgical excision as well as intracavitary carboplatin does not seem to be effective for the treatment of this thymic carcinoma subtype, with evidence of early recurrence and return of clinical signs.
Subject(s)
Carcinoma, Squamous Cell , Cat Diseases , Dog Diseases , Thymoma , Thymus Neoplasms , Male , Cats , Animals , Dogs , Thymoma/drug therapy , Thymoma/surgery , Thymoma/veterinary , Carboplatin/therapeutic use , Cat Diseases/diagnosis , Cat Diseases/surgery , Dog Diseases/drug therapy , Thymus Neoplasms/diagnosis , Thymus Neoplasms/therapy , Thymus Neoplasms/veterinary , Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/surgery , Carcinoma, Squamous Cell/veterinaryABSTRACT
High-grade and metastatic canine mast cell tumors carry a guarded prognosis because of their unpredictable biologic behavior. An ideal chemotherapy regime is yet to be established. The aim of this study was to review the efficacy and toxicity of combination vinblastine and toceranib for high-grade and metastatic mast cell tumors. Twenty-eight dogs were categorized with either high-grade, lymph node metastasis or Stage IV disease. Demographics, disease, and treatment variables were compared between categories (Kruskal-Wallis test for continuous data and Fisher's Exact test for categorical data). Survival times and progression-free intervals (PFI) were calculated and compared between groups (log rank test). The PFI was 310 d [95% confidence interval (CI): 155 to 1425] and overall survival was 373 d (95% CI: 226 to 1219). There was no difference between disease categories for PFI (P = 0.9) or survival (P = 0.5). The protocol was well-tolerated with increased liver enzyme activity and gastrointestinal toxicity most frequently observed. Progression-free intervals and survival times were similar in dogs with high-grade, metastatic and Stage IV disease.
Combinaison vinblastine et Palladia pour les mastocytomes métastatiques et de haut grade chez le chien. Les mastocytomes canins métastatiques et de haut grade ont un pronostic réservé en raison de leur comportement biologique imprévisible. Un traitement idéal de chimiothérapie n'a pas encore été établi. Le but de cette étude était d'examiner l'efficacité et la toxicité de l'association vinblastine et tocéranib pour les mastocytomes de haut grade et métastatiques.Vingt-huit chiens ont été classés soit avec une maladie de haut grade, des métastases ganglionnaires ou avec une maladie de stade IV. Les variables démographiques, de maladie et de traitement ont été comparées entre les catégories (test de Kruskal-Wallis pour les données continues et test exact de Fisher pour les données catégorielles). Les temps de survie et les intervalles sans progression (PFI) ont été calculés et comparés entre les groupes (test de log-rank). Le PFI était de 310 jours [intervalle de confiance à 95 % (IC): 155 à 1425] et la survie globale était de 373 jours (IC 95 %: 226 à 1219). Il n'y avait pas de différence entre les catégories de maladie pour le PFI (P = 0,9) ou la survie (P = 0,5). Le protocole a été bien toléré avec une augmentation de l'activité des enzymes hépatiques et une toxicité gastro-intestinale les plus fréquemment observées. Les PFI et les temps de survie étaient similaires chez les chiens atteints d'une maladie de haut grade, ceux avec des métastases et ceux de stade IV.(Traduit par Dr Serge Messier).
Subject(s)
Dog Diseases , Neoplasms , Animals , Dog Diseases/drug therapy , Dogs , Indoles , Mast Cells , Neoplasms/veterinary , Pyrroles , Retrospective Studies , Vinblastine/therapeutic useABSTRACT
CASE SUMMARY: Primary pancreatic adenocarcinoma is an uncommon neoplasm seen in cats and often has a poor prognosis. We report a case of an 8-year-old male neutered domestic shorthair cat weighing 5.8 kg diagnosed with pancreatic adenocarcinoma treated with surgical resection and toceranib phosphate, which had a progression-free interval of 1148 days and survived for more than 1436 days. The treatment was well tolerated; however, the cat developed generalised coat hypopigmentation. RELEVANCE AND NOVEL INFORMATION: To our knowledge, the cat in our report has the longest progression-free interval and survival time post-surgical resection of pancreatic carcinoma treated with toceranib. Hypopigmentation as a side effect of toceranib has been reported in dogs, but this is the first case reported in cats.
